5-fluoro-4-methylnicotinic acid | 1211584-22-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-fluoro-4-methylnicotinic acid
• 英文别名: 5-fluoro-4-Methylpyridine-3-carboxylic acid
• CAS: 1211584-22-3
• 化学式: C₇H₆FNO₂
• 分子量: 155.129
• InChiKey: GRIVFOODODSKMR-UHFFFAOYSA-N

物化性质

• 沸点：
  285.8±35.0 °C(Predicted)
• 密度：
  1.341±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-fluoro-4-methylnicotinic acid 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 5-fluoro-N-(5-(1-hydroxy-1-(4-methoxyphenyl)propyl)pyridin-2-yl)-4-methylnicotinamide
  参考文献：
  名称：

  Compounds for inflammation and immune-related uses

  摘要：

  该发明涉及某些化合物或其药用可接受的盐、溶剂合物、包合物或前药，这些化合物可用作免疫抑制剂，并用于治疗和预防炎症症状、过敏疾病和免疫紊乱。

  公开号：

  US09604978B2

文献信息

• [EN] 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] COMPOSÉS 6,7-DIHYDROPYRAZOLO[1,5-A] PYRAZIN-4(5H)-ONE ET LEUR UTILISATION COMME MODULATEURS ALLOSTÉRIQUES NÉGATIFS DES RÉCEPTEURS MGLUR2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2016016395A1

  公开（公告）日：2016-02-04

  The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

  本发明涉及新型的6,7-二氢吡唑[1,5-a]吡嗪-4(5H)-酮衍生物，作为代谢型谷氨酸受体2型("mGluR2")的负变构调节剂(NAMs)。该发明还涉及包含这些化合物的药物组合物，制备这些化合物和组合物的方法，以及使用这些化合物和组合物预防或治疗涉及代谢型受体mGluR2亚型的疾病。
• [EN] CXCR3 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR CXCR3
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010126851A1

  公开（公告）日：2010-11-04

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6, A, B, X, Y and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式（I）的化合物及其药用盐，其中R1至R6、A、B、X、Y和n的定义如本文所述。该发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES
  申请人：Chen Shoujun

  公开号：US20140171446A1

  公开（公告）日：2014-06-19

  The invention relates to certain compounds or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

  本发明涉及某些化合物或其药学上可接受的盐、溶剂合物、包合物或前药，其作为免疫抑制剂和用于治疗和预防炎症病症、过敏性疾病和免疫性疾病具有用途。
• HETEROCYCLIC METHYL SULFONE DERIVATIVE
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1640366A1

  公开（公告）日：2006-03-29

  Provided is a compound capable of inhibiting production or secretion of β amyloid protein. A compound represented by the following formula (1): (wherein, R1 represents a heterocyclic group which may have a substituent, R2 represents a cyclic hydrocarbon group which may have a substituent or a heterocyclic group which may have a substituent, R3 represents a cyclic hydrocarbon group which may have a substituent or a heterocyclic group which may have a substituent, R4 represents a hydrogen atom or a C1-6 alkyl group, and X represents -S-,-SO- or -SO2-) an N-oxide or S-oxide thereof; a salt thereof; or a solvate thereof; and a medicament containing any of them.

  本发明提供了一种能够抑制β淀粉样蛋白产生或分泌的化合物。 由下式（1）代表的化合物： (其中，R1代表可具有取代基的杂环基团，R2代表可具有取代基的环烃基团或可具有取代基的杂环基团，R3代表可具有取代基的环烃基团或可具有取代基的杂环基团，R4代表氢原子或C1-6烷基，X代表-S-、-SO-或-SO2-)其N-氧化物或S-氧化物；其盐；或其溶液；以及含有其中任何一种的药物。
• Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors
  申请人：Janssen Pharmaceutica NV

  公开号：US10005785B2

  公开（公告）日：2018-06-26

  The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I) as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

  本发明涉及式 (I) 的新型 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮衍生物 作为代谢型谷氨酸受体亚型 2（"mGluR2"）的负异位调节剂（NAMs）。本发明还涉及包含此类化合物的药物组合物、制备此类化合物和组合物的工艺，以及使用此类化合物和组合物预防或治疗涉及代谢型受体 mGluR2 亚型的疾病。